Medullary Thyroid Cancer - Pipeline Review, H2 2014

Global Markets Direct
July 31, 2014
105 Pages - SKU: GMD5308233
Medullary Thyroid Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Medullary Thyroid Cancer - Pipeline Review, H2 2014’, provides an overview of the Medullary Thyroid Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Additional Information

Companies Mentioned

Boehringer Ingelheim GmbH
AstraZeneca PLC
Novartis AG
Immunomedics, Inc.
Ariad Pharmaceuticals, Inc.
Nerviano Medical Sciences
Advenchen Laboratories, LLC
Globeimmune, Inc.

Country

More Oncology/Hematology reports by Global Markets Direct

Cancer Cachexia - Pipeline Review, H2 2014 by Global Markets Direct
Cancer Cachexia - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Cancer Cachexia - Pipeline Review, H2 2014’, provides an overview of the Cancer Cachexia’s therapeutic pipeline.This ...
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014 by Global Markets Direct
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014’, provides an overview of the ...
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2014 by Global Markets Direct
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) ...
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014 by Global Markets Direct
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014’, provides an overview of the ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 2,000  
    Site License  USD 4,000  
    Global Site License  USD 6,000  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!